Jiangsu Hengrui Pharmaceuticals (600276.SH): SHR-3836 injection obtained drug clinical trial batch.

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary, Shanghai Jiangsu Hengrui Pharmaceuticals Co., Ltd., has received approval from the National Medical Products Administration (NMPA) for the clinical trial of SHR-3836 injection. The company will soon begin the clinical trial. SHR-3836 injection is an innovative anti-tumor drug developed by the company, intended for the treatment of multiple myeloma. Currently, there are no similar drugs on the market both domestically and internationally. As of now, the cumulative research and development investment for SHR-3836 injection is approximately 31.7 million yuan (unaudited).